Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved Encelto ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. KOLOA, Hawaii — In this Healio Video Perspective from ...
The eye condition, which can induce the loss of central vision, could see effective treatment options pending FDA approval. Macular telangiectasia (MacTel) has long gone without a consensus treatment ...
The Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) in the treatment of macular telangiectasia type 2 ...
The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular telangiectasia type 2 (MacTel), clinical investigator Charles C. Wykoff, MD, ...
Protein therapies for the eye must be dosed as frequent injections. Gene therapy offers one-time treatment, but must also be administered by injection. Neurotech Pharmaceuticals’ gene therapy comes in ...
John A. Moran Eye Center retinal specialist and researcher Paul S. Bernstein, MD, PhD, diagnosed John Ehrman with a rare eye disease known as Macular Telangiectasia Type 2 (MacTel) in 2014. The ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA granted priority review of the biologics license ...
Eye image of a patient with macular telangiectasia type 2, showing tiny crystal-like deposits and abnormal blood vessels in the retina. LA JOLLA, CA—For people diagnosed with macular telangiectasia ...
AVALA Hospital, in partnership with Retina Associates New Orleans, has successfully performed Louisiana’s first ENCELTO procedure, a cell-based gene therapy for adults with macular telangiectasia type ...
LA JOLLA, CA—For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results